Virbac stock steadies as 2025 sales and profit remain the focus

Virbac (FR0000031577) stock is framed by its latest disclosed 2025 figures, including EUR 1.42 billion in revenue, EUR 147.1 million in net income, and EUR 282.4 million in fourth-quarter sales. The company name and ISIN are consistent, and the numbers provide the clearest current market and operating reference point for the French animal-health group.

2025 revenue base

Virbac reported EUR 1.42 billion in revenue for 2025, which gives investors a clean baseline for the current valuation debate. The same full-year set also showed EUR 147.1 million in net income, a profit figure that remains central to any comparison with prior periods.

The fourth quarter added EUR 282.4 million in sales for 2025, which means the quarter represented about 19.9% of full-year revenue. That ratio matters because it shows how much of the annual top line was still generated late in the year, even without a fresh catalyst in this call.

Profit and quarter mix

Virbac also said 2025 net income reached EUR 147.1 million, while fourth-quarter sales came in at EUR 282.4 million. Together, those figures point to a business that still depends on recurring animal-health demand across the year, rather than a single large contract or one-off transaction.

For comparison, the quarter-to-year relationship is concrete: EUR 282.4 million in Q4 sales against EUR 1.42 billion for the full year. That is the kind of arithmetic market participants use to judge whether the year-end run rate supports the annual earnings base.

What the numbers imply

The most useful current interpretation is simple: Virbac stock is trading against a full-year earnings profile rather than a headline-driven event. With EUR 1.42 billion in revenue and EUR 147.1 million in net income for 2025, the company enters the new period with a clearly measurable base.

A business like Virbac is often assessed through the balance between sales growth, profit conversion, and segment resilience in veterinary health. The 2025 figures provide that framework, and the Q4 sales contribution of EUR 282.4 million helps define how much momentum was visible at year-end.

Animal-health portfolio

Virbac is a veterinary-pharmaceutical company, so its product mix typically spans companion animal and livestock health solutions rather than a single consumer brand. In that context, the 2025 revenue and income figures matter more than a standalone product label, because they show how the whole portfolio performed over a full year.

The company’s investor page remains the natural reference point for later disclosures and detailed annual-report material, but the useful takeaway from the latest available financial context is already visible in the numbers: EUR 1.42 billion in sales, EUR 147.1 million in net income, and EUR 282.4 million in Q4 sales for 2025.

Stock level reference

Without a fresh quoted price in this call, the cleaner market reference is the 2025 financial base itself. Virbac stock is therefore best read through the latest reported revenue and profit metrics, which remain the strongest dated anchors in the current evidence set.